Director/PDMR Shareholding

RNS Number : 9686L
MGC Pharmaceuticals Limited
18 May 2022
 

MGC Pharmaceuticals Ltd.

PDMR Notification

18 May 2022

ASX, LSE: MXC

 

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') wishes to advise that the following Person Discharging Managerial Responsibilities (PDMR) has dealt with shares in MGC Pharma, and this notification is made in accordance the UK Market Abuse Regulations.

The shares the subject of this notice were issued to the PDMR in accordance with a Share Purchase Agreement executed by MGC Pharma and the owners of MediCaNL Inc in April 2021, with the issued shares being the final tranche of deferred consideration payable by MGC Pharma to the PDMR who was a shareholder of MediCaNL Inc.

 

1

Details of the person discharging managerial responsibilities/person closely associated

 

(a)

Name

Nadya Lisovoder

2

Reason for the notification

 

(a)

Position

 

Chief Medical Officer

(b)

Initial notification/amendment

 

Initial

(c)

If amendment: reason

 

n/a

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor


Full name of entity

MGC Pharmaceuticals Limited

 


Legal Entity Identifier Code

213800HRE3FQJ6RK4H10

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted

 

(a)

Description of the financial instrument, type of instrument

Fully Paid Ordinary Shares

(b)

Identification Code (ISIN)

 

AU000000MXC6

(c)

Nature of transaction

Shares issued as consideration for a corporate entity acquired by the Issuer.

(d)

Currency

Price

Volume

Total


AUD

$0.067

6,721,179

450,319


Aggregated information


AUD

$0.067

6,721,179

450,319

(e)

Date of transaction

 

2022-05-13

(f)

Place of transaction

 

Outside a trading venue

 

--Ends--



 

Authorised for release by the Executive Chair, for further information please contact:

MGC Pharmaceuticals Ltd

Roby Zomer

CEO & Managing Director

+61 8 6382 3390

info@mgcpharma.com.au

MGC Pharmaceuticals Ltd

David Lim

Company Secretary

+61 8 6382 3390

info@mgcpharma.com.au  

UK Broker - Turner Pope

Andy Thacker

+44 203 657 0050

info@turnerpope.com

UK PR Advisors - Tavistock

Charles Vivian / Tim Pearson

+44 207 920 3150

mgcpharma@tavistock.co.uk

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBBGDUSGBDGDI
UK 100

Latest directors dealings